James LaValle, chair of the International Peptide Society, notes how the advisory committee's favorable vote on peptides for the 503A Bulks List was a meaningful step without constituting approval.
James LaValle
Advertisement
Jim LaValle, RPh, CCN, is a clinical pharmacist, board-certified nutritionist, and author with 40+ years of experience. He specializes in precision and performance health, integrating metabolic-based care. Founder of Metabolic Code Enterprises, he has taught at institutions like the University of Cincinnati and George Washington School of Medicine. LaValle has worked with elite sports teams, military, and first responders, optimizing performance and recovery. He has authored 26 books, including Cracking the Metabolic Code, and over 200 articles. Currently, he serves as Chief Science Officer at Life Time, leading scientific initiatives for its longevity and performance program, MIORA.
Articles by James LaValle
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: IntraGel & UroGen Sign Collaboration & Investment Agreements, Lupin & Tenpoint Form Commercialization Collaboration
2
Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly
3
Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb
4
When Drug Pricing Becomes Trade Policy
5